Duration of migraine is a predictor for response to botulinum toxin type A

Eric J. Eross, Jonathan P. Gladstone, Susan Lewis, Robert Rogers, David William Dodick

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective. - To identify the clinical characteristics and/or injection parameters that predict a favorable response to botulinum toxin type A in patients with episodic and chronic migraine. Background. - There is emerging scientific and clinical evidence to support the utility of botulinum toxin type A (BoNT-A) in the prophylaxis of episodic and chronic migraine headache. However, the patient characteristics and injection strategies that predict a favorable treatment response are unknown. Methods. - We conducted a prospective, open-label study on 74 patients from our clinic receiving BoNT-A for episodic or chronic migraine. For all patients, migraine-related disability (Migraine Disability Assesment [MIDAS]), headache frequency, and average headache intensity were obtained at baseline and at 3 months post-BoNT-A. Information regarding demographic characteristics and injection parameters was also collected. Results. - Sixty-one patients met the study criteria and were available for 3-month follow-up. At the 3-month follow-up visit, the mean MIDAS scores of the 61 qualified study patients had decreased from 102 at baseline to 49 (52% decrease, P < .001). The mean number of headache days was reduced from 60 to 39 (P < .001), and the mean headache intensity decreased from 7.6 at baseline to 5.9 (P < .001). Frequency of migraine attacks, presence of analgesic overuse, total BoNT-A dose, and presence of underlying muscle tenderness were not predictive of treatment response. Age and duration of migraine were the only clinical factors significantly predictive of treatment response. Age likely was a predictor only as a consequence of duration of illness as subjects with migraine duration greater than 30 years were significantly less likely to respond to treatment with BoNT-A. Conclusion. - BoNT-A may be effective in decreasing headache frequency, headache intensity, and headache-related disability in episodic and chronic migraine patients. Duration of illness emerged as a predictor of treatment response. Randomized controlled studies should evaluate headache-related disability as a primary endpoint in patients with episodic and chronic headache.

Original languageEnglish (US)
Pages (from-to)308-314
Number of pages7
JournalHeadache
Volume45
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Type A Botulinum Toxins
Migraine Disorders
Headache
Headache Disorders
Injections
Therapeutics
Myalgia
Analgesics
Demography

Keywords

  • BOTOX
  • Botulinum toxin type A
  • Chronic migraine
  • Migraine
  • Prophylactic therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Duration of migraine is a predictor for response to botulinum toxin type A. / Eross, Eric J.; Gladstone, Jonathan P.; Lewis, Susan; Rogers, Robert; Dodick, David William.

In: Headache, Vol. 45, No. 4, 04.2005, p. 308-314.

Research output: Contribution to journalArticle

Eross, Eric J. ; Gladstone, Jonathan P. ; Lewis, Susan ; Rogers, Robert ; Dodick, David William. / Duration of migraine is a predictor for response to botulinum toxin type A. In: Headache. 2005 ; Vol. 45, No. 4. pp. 308-314.
@article{ef172ec6dbc246339accf4288a441107,
title = "Duration of migraine is a predictor for response to botulinum toxin type A",
abstract = "Objective. - To identify the clinical characteristics and/or injection parameters that predict a favorable response to botulinum toxin type A in patients with episodic and chronic migraine. Background. - There is emerging scientific and clinical evidence to support the utility of botulinum toxin type A (BoNT-A) in the prophylaxis of episodic and chronic migraine headache. However, the patient characteristics and injection strategies that predict a favorable treatment response are unknown. Methods. - We conducted a prospective, open-label study on 74 patients from our clinic receiving BoNT-A for episodic or chronic migraine. For all patients, migraine-related disability (Migraine Disability Assesment [MIDAS]), headache frequency, and average headache intensity were obtained at baseline and at 3 months post-BoNT-A. Information regarding demographic characteristics and injection parameters was also collected. Results. - Sixty-one patients met the study criteria and were available for 3-month follow-up. At the 3-month follow-up visit, the mean MIDAS scores of the 61 qualified study patients had decreased from 102 at baseline to 49 (52{\%} decrease, P < .001). The mean number of headache days was reduced from 60 to 39 (P < .001), and the mean headache intensity decreased from 7.6 at baseline to 5.9 (P < .001). Frequency of migraine attacks, presence of analgesic overuse, total BoNT-A dose, and presence of underlying muscle tenderness were not predictive of treatment response. Age and duration of migraine were the only clinical factors significantly predictive of treatment response. Age likely was a predictor only as a consequence of duration of illness as subjects with migraine duration greater than 30 years were significantly less likely to respond to treatment with BoNT-A. Conclusion. - BoNT-A may be effective in decreasing headache frequency, headache intensity, and headache-related disability in episodic and chronic migraine patients. Duration of illness emerged as a predictor of treatment response. Randomized controlled studies should evaluate headache-related disability as a primary endpoint in patients with episodic and chronic headache.",
keywords = "BOTOX, Botulinum toxin type A, Chronic migraine, Migraine, Prophylactic therapy",
author = "Eross, {Eric J.} and Gladstone, {Jonathan P.} and Susan Lewis and Robert Rogers and Dodick, {David William}",
year = "2005",
month = "4",
doi = "10.1111/j.1526-4610.2005.05067.x",
language = "English (US)",
volume = "45",
pages = "308--314",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Duration of migraine is a predictor for response to botulinum toxin type A

AU - Eross, Eric J.

AU - Gladstone, Jonathan P.

AU - Lewis, Susan

AU - Rogers, Robert

AU - Dodick, David William

PY - 2005/4

Y1 - 2005/4

N2 - Objective. - To identify the clinical characteristics and/or injection parameters that predict a favorable response to botulinum toxin type A in patients with episodic and chronic migraine. Background. - There is emerging scientific and clinical evidence to support the utility of botulinum toxin type A (BoNT-A) in the prophylaxis of episodic and chronic migraine headache. However, the patient characteristics and injection strategies that predict a favorable treatment response are unknown. Methods. - We conducted a prospective, open-label study on 74 patients from our clinic receiving BoNT-A for episodic or chronic migraine. For all patients, migraine-related disability (Migraine Disability Assesment [MIDAS]), headache frequency, and average headache intensity were obtained at baseline and at 3 months post-BoNT-A. Information regarding demographic characteristics and injection parameters was also collected. Results. - Sixty-one patients met the study criteria and were available for 3-month follow-up. At the 3-month follow-up visit, the mean MIDAS scores of the 61 qualified study patients had decreased from 102 at baseline to 49 (52% decrease, P < .001). The mean number of headache days was reduced from 60 to 39 (P < .001), and the mean headache intensity decreased from 7.6 at baseline to 5.9 (P < .001). Frequency of migraine attacks, presence of analgesic overuse, total BoNT-A dose, and presence of underlying muscle tenderness were not predictive of treatment response. Age and duration of migraine were the only clinical factors significantly predictive of treatment response. Age likely was a predictor only as a consequence of duration of illness as subjects with migraine duration greater than 30 years were significantly less likely to respond to treatment with BoNT-A. Conclusion. - BoNT-A may be effective in decreasing headache frequency, headache intensity, and headache-related disability in episodic and chronic migraine patients. Duration of illness emerged as a predictor of treatment response. Randomized controlled studies should evaluate headache-related disability as a primary endpoint in patients with episodic and chronic headache.

AB - Objective. - To identify the clinical characteristics and/or injection parameters that predict a favorable response to botulinum toxin type A in patients with episodic and chronic migraine. Background. - There is emerging scientific and clinical evidence to support the utility of botulinum toxin type A (BoNT-A) in the prophylaxis of episodic and chronic migraine headache. However, the patient characteristics and injection strategies that predict a favorable treatment response are unknown. Methods. - We conducted a prospective, open-label study on 74 patients from our clinic receiving BoNT-A for episodic or chronic migraine. For all patients, migraine-related disability (Migraine Disability Assesment [MIDAS]), headache frequency, and average headache intensity were obtained at baseline and at 3 months post-BoNT-A. Information regarding demographic characteristics and injection parameters was also collected. Results. - Sixty-one patients met the study criteria and were available for 3-month follow-up. At the 3-month follow-up visit, the mean MIDAS scores of the 61 qualified study patients had decreased from 102 at baseline to 49 (52% decrease, P < .001). The mean number of headache days was reduced from 60 to 39 (P < .001), and the mean headache intensity decreased from 7.6 at baseline to 5.9 (P < .001). Frequency of migraine attacks, presence of analgesic overuse, total BoNT-A dose, and presence of underlying muscle tenderness were not predictive of treatment response. Age and duration of migraine were the only clinical factors significantly predictive of treatment response. Age likely was a predictor only as a consequence of duration of illness as subjects with migraine duration greater than 30 years were significantly less likely to respond to treatment with BoNT-A. Conclusion. - BoNT-A may be effective in decreasing headache frequency, headache intensity, and headache-related disability in episodic and chronic migraine patients. Duration of illness emerged as a predictor of treatment response. Randomized controlled studies should evaluate headache-related disability as a primary endpoint in patients with episodic and chronic headache.

KW - BOTOX

KW - Botulinum toxin type A

KW - Chronic migraine

KW - Migraine

KW - Prophylactic therapy

UR - http://www.scopus.com/inward/record.url?scp=17244382526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17244382526&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2005.05067.x

DO - 10.1111/j.1526-4610.2005.05067.x

M3 - Article

VL - 45

SP - 308

EP - 314

JO - Headache

JF - Headache

SN - 0017-8748

IS - 4

ER -